Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024

Core Insights - Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, will release its financial results for Q2 2024 on July 31, 2024, after market close [1] - A conference call to discuss these results will be held at 1:30 p.m. PT / 4:30 p.m. ET on the same day [1] Company Overview - Pulmonx Corporation specializes in treatments for chronic obstructive pulmonary disease (COPD) and offers products such as the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, recognized as a standard treatment option for severe emphysema [3] - The company's products aim to improve breathing, activity levels, and quality of life for patients suffering from severe emphysema/COPD [3]